First Long Island Investors Increased Its Unitedhealth Group (UNH) Holding; 3 Analysts Bullish Emergent BioSolutions Inc. (EBS)

December 11, 2017 - By Michael Collier

First Long Island Investors Llc increased Unitedhealth Group Inc (UNH) stake by 16.56% reported in 2017Q2 SEC filing. First Long Island Investors Llc acquired 3,777 shares as Unitedhealth Group Inc (UNH)’s stock rose 9.50%. The First Long Island Investors Llc holds 26,589 shares with $4.93M value, up from 22,812 last quarter. Unitedhealth Group Inc now has $215.48B valuation. The stock decreased 0.69% or $1.55 during the last trading session, reaching $222.36. About 689,337 shares traded. UnitedHealth Group Incorporated (NYSE:UNH) has risen 32.76% since December 11, 2016 and is uptrending. It has outperformed by 16.06% the S&P500.

Among 4 analysts covering Emergent Biosolutions (NYSE:EBS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Emergent Biosolutions had 7 analyst reports since August 10, 2015 according to SRatingsIntel. The rating was initiated by Singular Research with “Buy” on Monday, March 28. Chardan Capital Markets initiated it with “Buy” rating and $47 target in Friday, April 15 report. Wells Fargo initiated Emergent BioSolutions Inc. (NYSE:EBS) on Friday, February 19 with “Outperform” rating. Cowen & Co maintained it with “Hold” rating and $3300 target in Friday, July 14 report. The firm has “Hold” rating by Zacks given on Monday, August 10. The stock of Emergent BioSolutions Inc. (NYSE:EBS) has “Buy” rating given on Tuesday, June 28 by Singular Research. See Emergent BioSolutions Inc. (NYSE:EBS) latest ratings:

14/07/2017 Broker: Cowen & Co Rating: Hold New Target: $33.0000 Maintain
14/07/2017 Broker: Wells Fargo Rating: Buy New Target: $41.0000

Investors sentiment increased to 1.69 in Q2 2017. Its up 0.12, from 1.57 in 2017Q1. It improved, as 17 investors sold Emergent BioSolutions Inc. shares while 44 reduced holdings. 25 funds opened positions while 71 raised stakes. 34.36 million shares or 0.98% more from 34.02 million shares in 2017Q1 were reported. California-based First Republic Mngmt has invested 0% in Emergent BioSolutions Inc. (NYSE:EBS). Aqr Capital Management Ltd Liability Corp reported 0.01% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Nuveen Asset Ltd Liability Corporation accumulated 71,473 shares or 0.02% of the stock. Alliancebernstein Ltd Partnership invested in 94,792 shares. The United Kingdom-based Aberdeen Asset Management Public Ltd Company Uk has invested 0.2% in Emergent BioSolutions Inc. (NYSE:EBS). Barclays Public Ltd Co invested 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Wharton Business Lc accumulated 0.04% or 11,927 shares. 18,900 were reported by Chatham Capital Group Inc Inc. Bnp Paribas Arbitrage stated it has 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS). Sector Pension Board holds 0.01% or 17,781 shares in its portfolio. Thrivent Finance For Lutherans invested in 0% or 20,970 shares. New Amsterdam Partners Limited Co holds 98,228 shares. Ny State Common Retirement Fund reported 0% in Emergent BioSolutions Inc. (NYSE:EBS). Comerica Bancshares stated it has 47,910 shares. Renaissance Tech Lc reported 0.04% in Emergent BioSolutions Inc. (NYSE:EBS).

The stock increased 2.11% or $0.92 during the last trading session, reaching $44.47. About 162,532 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has declined 23.64% since December 11, 2016 and is downtrending. It has underperformed by 40.34% the S&P500.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $1.84 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 24.76 P/E ratio. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.

Among 25 analysts covering UnitedHealth Group (NYSE:UNH), 25 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. UnitedHealth Group had 72 analyst reports since September 2, 2015 according to SRatingsIntel. Oppenheimer maintained the shares of UNH in report on Friday, July 7 with “Buy” rating. The stock of UnitedHealth Group Incorporated (NYSE:UNH) earned “Buy” rating by Credit Suisse on Friday, November 3. Vetr upgraded the stock to “Strong-Buy” rating in Wednesday, September 2 report. As per Thursday, June 16, the company rating was initiated by Bernstein. Mizuho downgraded UnitedHealth Group Incorporated (NYSE:UNH) on Wednesday, November 9 to “Neutral” rating. Credit Suisse initiated the shares of UNH in report on Wednesday, December 16 with “Outperform” rating. The stock of UnitedHealth Group Incorporated (NYSE:UNH) has “Buy” rating given on Tuesday, June 27 by Stifel Nicolaus. The firm has “Buy” rating by Leerink Swann given on Wednesday, October 18. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, November 16. The firm has “Overweight” rating given on Wednesday, October 18 by Morgan Stanley.

Investors sentiment decreased to 0.91 in Q2 2017. Its down 0.11, from 1.02 in 2017Q1. It worsened, as 53 investors sold UNH shares while 496 reduced holdings. 122 funds opened positions while 438 raised stakes. 816.36 million shares or 0.29% more from 813.97 million shares in 2017Q1 were reported. Ssi Inv Management owns 0.07% invested in UnitedHealth Group Incorporated (NYSE:UNH) for 4,164 shares. Grandfield & Dodd Ltd Liability Company has invested 0.39% in UnitedHealth Group Incorporated (NYSE:UNH). Doheny Asset Ca holds 1,154 shares. Gofen And Glossberg Limited Company Il stated it has 5,419 shares. Capital Ca invested 0.24% of its portfolio in UnitedHealth Group Incorporated (NYSE:UNH). Berkshire Asset Management Pa holds 7,450 shares or 0.16% of its portfolio. Butensky & Cohen Security Inc invested 0% of its portfolio in UnitedHealth Group Incorporated (NYSE:UNH). Tocqueville Asset Management LP reported 0.13% of its portfolio in UnitedHealth Group Incorporated (NYSE:UNH). Trilogy Global Lp accumulated 156,679 shares. Ellington Mngmt Gru Llc holds 0.06% in UnitedHealth Group Incorporated (NYSE:UNH) or 2,200 shares. Adirondack Tru Com holds 0.14% in UnitedHealth Group Incorporated (NYSE:UNH) or 915 shares. Daiwa Securities Group has invested 0.13% of its portfolio in UnitedHealth Group Incorporated (NYSE:UNH). South State holds 0.11% of its portfolio in UnitedHealth Group Incorporated (NYSE:UNH) for 4,639 shares. Barrett Asset Management Ltd Com owns 6,504 shares or 0.09% of their US portfolio. Principal Financial Grp Inc Inc, a Iowa-based fund reported 1.68 million shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com